Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas
Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Maria Grazia Bernengo(University of Turin), Marco Santucci(University of Florence), Alessandro Pileri(Azienda USL di Bologna), Mauro Alaibac(University of Padua), G. Borroni(University of Milan), Maria Teresa Fierro(University of Turin), Renato Alterini(University of Milan), Stefano Pileri(European Institute of Oncology), Lapo Alinari(University of Milan), N Cappello(University of Milan), Serena Rupoli(Unknown), Maurizio Martelli(University of Milan), Pietro Quaglino(Department of Medical Sciences), Davide Soligo(University of Milan), Emilio Berti(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Gianandrea Baliva(University of Milan), Nicola Pimpinelli(University of Florence), Sergio Chimenti(University of Milan), Marco Paulli(University of Milan)
Cited by 230
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Defining early mycosis fungoides
|Journal of the American Academy of Dermatology|2005|543
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523